N/A
N=51
Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
Chronic Obstructive Pulmonary Disease
Bottom Line
View on ClinicalTrials.gov: NCT01933984 ↗Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: ∆Raw (the Difference Between Measured and Target Airway Resistance) — 9; 44 percentage of relative Raw deviation
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bronchodilators inhalation (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Shin-hwar Wu
- Primary completion
- Jan 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ∆Raw (the Difference Between Measured and Target Airway Resistance) |
9; 44 | — |
| PRIMARY Rapidity of ∆Raw Change |
-3; 0.4 | — |
| SECONDARY Ventilator-free Days From Day 1 to 28 |
19; 22 | — |
| SECONDARY The Participants of Breathing Without Assistance by Day 28 |
19; 22 | — |
| SECONDARY Number of Episode of Nosocomial Pneumonia |
0; 0 | — |
| SECONDARY Number of Total Puff of Rescue Short-acting Bronchodilator |
0; 0 | — |
| SECONDARY Numbers of Episode of Drug-related Adverse Effect |
0; 0 | — |
| SECONDARY Mortality Rate |
35; 40 | — |
Summary
This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more effective than fixed dosing in reducing airway resistance of intubated COPD patients.
Eligibility Criteria
Inclusion Criteria
- chronic obstructive pulmonary disease
- acute respiratory failure under ventilator support for less than 72 hours
- endotracheal tube inserted
Exclusion Criteria
- confirmed asthma
- Acute Physiology and Chronic Health Evaluation II score over 35
- a co-morbidity of septic shock
Data sourced from ClinicalTrials.gov (NCT01933984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.